March 27, 2024 - Page 6 of 15

NASDAQ Companies - March 27, 2024

Dyne Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed President and Chief Executive Officer

WALTHAM, Mass., March 27, 2024 (GLOBE NEWSWIRE) — Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on […]

NASDAQ Companies - March 27, 2024

NeuroPace to Present at the Needham 23rd Annual Healthcare Conference

MOUNTAIN VIEW, Calif., March 27, 2024 (GLOBE NEWSWIRE) — NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming […]

NASDAQ Companies - March 27, 2024

RxSight, Inc. to Participate in the 23rd Annual Needham Virtual Healthcare Conference

ALISO VIEJO, Calif., March 27, 2024 (GLOBE NEWSWIRE) — (NASDAQ: RXST) RxSight, Inc., an ophthalmic medical device company dedicated to providing […]

TSX Venture News - March 27, 2024

Rakovina Therapeutics Announces Strategic Pivot to AI

VANCOUVER, British Columbia, March 27, 2024 (GLOBE NEWSWIRE) — Rakovina Therapeutics Inc. (TSX-V: RKV), (“Rakovina” or the “Company”), a biopharmaceutical […]

NYSE Companies - March 27, 2024

Tyson Foods Announces Second Quarter Earnings Conference Call and Webcast

SPRINGDALE, Ark., March 27, 2024 (GLOBE NEWSWIRE) — Tyson Foods, Inc. (NYSE: TSN) will release second quarter 2024 financial results […]

NYSE Companies - March 27, 2024

Matinas BioPharma Reports 2023 Financial Results and Provides a Business Update

Clear registration pathway and FDA agreement on the ORALTO Phase 3 trial for MAT2203 represent critical steps forward and supports […]

NASDAQ Companies - March 27, 2024

Mereo BioPharma Reports Full Year 2023 Financial Results and Provides Corporate Update

Phase 2/3 Orbit Study and Phase 3 Cosmic Study of setrusumab in Osteogenesis Imperfecta expected to complete enrollment around the […]

NASDAQ Companies - March 27, 2024

Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 Million

Avalo acquires Phase 2-ready anti-IL-1β mAb, AVTX-009, through acquisition of AlmataBio, Inc. Topline results from planned Phase 2 trial in […]

NASDAQ Companies - March 27, 2024

Celcuity Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Dosed the first patient in a Phase 1b/2 trial evaluating gedatolisib in combination with darolutamide for the treatment of metastatic […]

NASDAQ Companies - March 27, 2024

Erasca Reports Fourth Quarter 2023 and Full Year 2023 Business Updates and Financial Results

Gained global registrational clarity for naporafenib and achieved key clinical milestones for naporafenib, ERAS-007, and ERAS-801 Multiple data readouts expected […]